$IDRA News

Last published 3y ago

3y agoIDRAIdera Pharmaceuticals Announces Name Change to Aceragen, Inc. and Provides Near-Term Strategic OutlookGlobeNewswireCompany completes preferred stock conversion, implements reverse stock split, and regains Nasdaq compliance Company positioned for success with late-stage rare disease portfolio and multiple clinical milestones in
4y agoIDRAIdera Pharmaceuticals Acquires AceragenGlobeNewswireAcquisition includes late-stage rare disease portfolio with anticipated 2023 clinical milestones and first potential product approval as early as late 2024 Conference call and webcast today at 5:00 p.m. ET EXTON, Pa. and DURHAM, N.C., Sept. 28, 20
4y agoIDRAIdera Pharmaceuticals Reports Second Quarter 2022 Financial ResultsGlobeNewswireEXTON, Pa., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. ("Idera," the "Company," "we," "us," or "our") (NASDAQ:IDRA) today reported its financial and operational results for the second quarter ended June 30, 2022. Second Quarter Fi
4y agoIDRAIdera Pharmaceuticals Shares Positive Results from Investigator-Sponsored Trial in Melanoma Patients at Amsterdam UMCGlobeNewswireEXTON, Pa., May 17, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. ("Idera," "we," and "our") (NASDAQ:IDRA) today shared positive interim results from Amsterdam UMC, Vrije Universiteit Amsterdam, the Netherlands, regarding its investigator-sponso
4y agoIDRAIdera Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewswireEXTON, Pa., May 05, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. ("Idera," the "Company," "we," "us," or "our") (NASDAQ:IDRA) today reported its financial and operational results for the first quarter ended March 31, 2022. "We continue to pr
4y agoIDRAIdera Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate UpdateGlobeNewswireEXTON, Pa., March 31, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. ("Idera," the "Company," "we," "us," or "our") (NASDAQ:IDRA) today reported its financial and operational results for the fourth quarter and year ended December 31, 2021. "We
4y agoBBIG HMHC IDRA PSTI+1Thinking about buying stock in Surgalign, Pluristem Therapeutics, Houghton Mifflin Harcourt, Idera Pharmaceuticals, or Vinco Ventures?PR NewswireNEW YORK, Jan. 18, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SRGA, PSTI, HMHC, IDRA, and BBIG.
4y agoIDRAIdera Pharmaceuticals Announces Tilsotolimod UpdatesGlobeNewswireEXTON, Pa., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. ("Idera," the "Company," "we," "us," and "our") (NASDAQ:IDRA) today announced clinical updates regarding tilsotolimod, its synthetic Toll-like receptor 9 agonist. ILLUMINATE-2
5y agoIDRAIdera Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewswireEXTON, Pa., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. ("Idera," the "Company," "we," "us," or "our") (NASDAQ:IDRA) today reported its financial and operational results for the third quarter ended September 30, 2021. "We are m
5y agoENTX IDRA NKLA ORPH+1Thinking about buying stock in Entera Bio, Torchlight Energy, Idera Pharmaceuticals, Nikola Corp, or Orphazyme?PR NewswireNEW YORK, June 23, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ENTX, TRCH, IDRA, NKLA, and ORPH.
5y agoBIOC CLOV HSTO IDRA+1Thinking about buying stock in Biocept, Histogen, Idera Pharmaceuticals, Satsuma Pharmaceuticals, or Clover Health Investments?PR NewswireNEW YORK, June 22, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BIOC, HSTO, IDRA, STSA, and CLOV. T
5y agoIDRAIdera Pharmaceuticals Announces Corporate UpdatesGlobeNewswireEXTON, Pa., May 18, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. ("Idera" or the "Company") (NASDAQ:IDRA) today announced that it will not continue ILLUMINATE-301, the Company's trial of tilsotolimod in combination with ipilimumab versus ipilim
5y agoIDRAIdera Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewswireEXTON, Pa., April 29, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. ("Idera" or the "Company") (NASDAQ:IDRA) today reported its financial and operational results for the first quarter ended March 31, 2021. "Despite the disappointing objective
5y agoVYNT KYMR LQDA IDRA+1Vyant Bio Announces Newly Appointed Board of DirectorsGlobeNewswireCHERRY HILL, N.J., April 05, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (the “Company”) (Nasdaq: VYNT), is a new force in drug discovery, focused on integrating human-powered scientific and...
5y agoSNES SPCB CLVS IDRALatest Biotech Flop Shows Risks of Trading in Penny StocksBloombergWall Street didn’t see this one coming but retail traders might have, as one tiny biotech saw its value sliced in half overnight on disappointing results for its only medicine in clinical testing.
5y agoIDRAIdera Pharmaceuticals Announces Results From ILLUMINATE-301 Trial of Tilsotolimod + Ipilimumab in anti-PD-1 Refractory Advanced MelanomaGlobeNewswireEXTON, Pa., March 18, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA; the “Company”) today is announcing that ILLUMINATE-301, the Company’s pivotal registration trial of...
5y agoIDRAIdera Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate UpdateGlobeNewswireEXTON, Pa., March 01, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the fourth quarter and...
5y agoIDRAIdera Pharmaceuticals to Present at Upcoming ConferencesGlobeNewswireEXTON, Pa., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that it will provide a company outlook for 2021 at upcoming conferences. “2021 represents a...
5y agoIDRAIdera Pharmaceuticals Announces $5.0 Million in Further Proceeds from Private Placement of up to $20.7 MillionGlobeNewswireEXTON, Pa., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced the closing of a second tranche under its April 7, 2020, securities purchase agreement (the...
5y agoIDRAIdera Pharmaceuticals Announces Dan Soland to Join as Chief Operating OfficerGlobeNewswire– COO Role is Key to Preparedness for NDA Filing and Commercial Launch –– Clayton Fletcher, Head of Business Development & Strategic Planning, to Retire – EXTON, Pa., Nov. 17, 2020 (GLOBE...
6y agoIDRAIdera Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate UpdateGlobeNewswireEXTON, Pa., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the third quarter ended...
6y agoIDRAIdera Pharmaceuticals Announces New U.S. Patent Coverage for Tilsotolimod Through September 2037GlobeNewswireEXTON, Pa., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,772,907 (the ‘907...
6y agoIDRAIdera Pharmaceuticals to Present Tilsotolimod Data at ESMO Virtual Congress 2020GlobeNewswireFinal data from ILLUMINATE-204 trial in advanced melanoma and final results from ILLUMINATE-101 trial in refractory solid tumors to be presentedAbbVie to present a trial-in-progress poster of ABBV-368...
6y agoIDRAIdera Pharmaceuticals Reports Second Quarter Financial Results and Provides Corporate UpdateGlobeNewswireEXTON, Pa., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the second quarter ended...
6y agoIDRAIdera Pharmaceuticals Announces Private Placement of up to $20.0 MillionGlobeNewswireEXTON, Pa., July 15, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced entering into an agreement with a fund affiliated with institutional investors providing for...
6y agoIDRAIdera Pharmaceuticals Announces Preliminary Data From and Planned Continuation of the ILLUMINATE-206 Trial for the Treatment of Micro-Satellite Stable Colorectal CancerGlobeNewswireEXTON, Pa., June 02, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA; the “Company”) today announced preliminary data from the first 10 patients in the safety cohort of ...
6y agoIDRAIdera Pharmaceuticals Announces Change of Location for 2020 Annual Meeting of StockholdersGlobeNewswireEXTON, Pa., May 01, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today provided notice of a change in the location for its 2020 Annual Meeting of...
6y agoIDRAIdera Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate UpdateGlobeNewswireEXTON, Pa., April 30, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the first quarter ended...
6y agoIDRAIdera Pharmaceuticals Announces Final Clinical Safety and Efficacy Data from ILLUMINATE-204 Trial in Advanced MelanomaGlobeNewswire– Overall response rate of 22% –– Disease control rate of 71% –– Median overall survival of 21 months –– Key topline data from ILLUMINATE-301 expected in Q1 2021 – EXTON, Pa., April 21, 2020 ...
6y agoIDRAIdera Pharmaceuticals Announces Private Placement of up to $20.7 MillionGlobeNewswireEXTON, Pa., April 07, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced entering into an agreement with a fund affiliated with an institutional investor providing...
6y agoXERS XBIT VYGR SUPN+19In Biotech ‘Cash Is King’ When Wall Street Searches for ValueBloombergFor investors looking for deals in biotech, Wall Street firms like Baird advise “cash is king.”
6y agoIDRAIdera Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate UpdateGlobeNewswireEXTON, Pa., March 12, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ: IDRA) reported on March 11, 2020 its financial and operational results for the fourth quarter and year...
6y agoIDRAIdera Pharmaceuticals Provides 2020 Update and OutlookGlobeNewswireEXTON, Pa., Jan. 14, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), or Idera or the Company, today is providing an update on its tilsotolimod clinical development program and...
6y agoIDRA MSFT ORCL SAPGlobal Database Automation Market Analysis, Trends, and Forecasts 2019-2025 - ResearchAndMarkets.comBusiness WireDUBLIN--(BUSINESS WIRE)--The "Database Automation - Market Analysis, Trends, and Forecasts" report has been added to ResearchAndMarkets.com's offering.
6y agoIDRAIdera Pharmaceuticals Announces Private Placement Up To $97.7 MillionGlobeNewswireEXTON, Pa., Dec. 23, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), or the Company, announced today it is entering into an agreement with funds affiliated with an institutional...
7y agoIDRAIdera Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2019 Financial ResultsGlobeNewswireEXTON, Pa., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ: IDRA), a clinical-stage biopharmaceutical company focused on the development, and ultimately the...
7y agoIDRAIdera Pharmaceuticals Announces New U.S. Patent For Tilsotolimod Through September 2037GlobeNewswireEXTON, Pa., Oct. 21, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), or the Company, announced today that the U.S. Patent and Trademark Office will issue on November 5, 2019...
7y agoIDRAIdera Pharmaceuticals Announces Initiation of the ILLUMINATE-206 Trial Evaluating Tilsotolimod in Combination with Nivolumab and Ipilimumab for the Treatment of Solid TumorsGlobeNewswireEXTON, Pa., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) announced today the initiation of a phase 2 trial, ILLUMINATE-206 which will evaluate tilsotolimod, a...
7y agoIDRAIdera Pharmaceuticals to Present at the Baird 2019 Global Healthcare ConferenceGlobeNewswireEXTON, Pa., Aug. 30, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that the company will present at the Baird 2019 Global Healthcare Conference on Wednesday,...
7y agoIDRAIdera Pharmaceuticals, Inc. (IDRA) CEO Vincent Milano on Q2 2019 Results - Earnings Call TranscriptEarnings Call Transcripts
7y agoIDRAIdera Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2019 Financial ResultsGlobeNewswireEXTON, Pa., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ: IDRA), a clinical-stage biopharmaceutical company focused on the development, and ultimately the...
8y agoBCRX IDRABioCryst Provides Update on Strategy, Pipeline and OutlookBusiness WireRESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) (“BioCryst” or the “Company”), a pharmaceutical company focused on the development and commercialization of treatments for rare diseases, today provided an update on the Company’s strategic and financial outlook as a standalone company following the recent termination of its merger agreement with Idera Phar ...
8y agoBCRX IDRABioCryst Pharmaceuticals Announces Termination of Merger Agreement with Idera PharmaceuticalsBusiness WireRESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) (“BioCryst”) today announced that it has terminated the previously announced merger agreement with Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) (“Idera”) following the BioCryst stockholders’ failure to approve the adoption of the merger agreement at the BioCryst Special Meeting of Stockholders held today.
8y agoMDSO IDRAIdera Pharmaceuticals Increases Operational Efficiency of Global Oncology Program with Medidata Clinical CloudBusiness WireNEW YORK--(BUSINESS WIRE)--Medidata (NASDAQ:MDSO) today announced that Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), expanded its use of the Medidata Clinical Cloud® to automate operations, increase efficiencies, and gain better data visibility in order to accelerate their 2125 oncology development program.
8y agoBCRX IDRABioCryst Pharmaceuticals and Idera Pharmaceuticals Reschedule Meetings to Vote on Proposed MergerBusiness WireRESEARCH TRIANGLE PARK, N.C. & EXTON, Pa.--(BUSINESS WIRE)--BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) (“BioCryst”) and Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) (“Idera”) today jointly announced that they have each rescheduled their respective Special Meetings of Stockholders (each, a “Special Meeting”) to vote on the proposed merger of BioCryst and Idera to July 10, 2018 at 10:00 AM ET.
10y agoIDRAIdera Pharmaceuticals' (IDRA) CEO Vincent Milano on Q1 2016 Results - Earnings Call TranscriptEarnings Call Transcripts